Antibiotic Resistance - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antibiotic Resistance - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antibiotic Resistance Market By Disease (Urinary Tract Infection, Bloodstream Infection, Hospital Acquired Pneumonia, And Others), Therapeutic Class (Tetracyclines, Floroquinolones, Amphenicols, Oxazolidinones, And Others), Distribution (Hospital Pharmacies, Retail Pharmacies, And Online Pharmacies), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing burden of antibiotic resistance infection and growing government initiatives

The global antibiotic resistance market is estimated to grow at a CAGR of 5.65% during the forecast period from 2024 to 2030. The escalating burden of antibiotic-resistant infections stands as a significant driver behind the positive growth observed in the antibiotic resistance market. Furthermore, the increasing misuse and overuse of antibiotics across human, animal, and plant sectors emerge as primary contributing factors to this upward trend during the forecast period spanning from 2024 to 2030.

Antibiotic Resistance Market Dynamics:

As highlighted in the 2023 report by the World Health Organization (WHO), antimicrobial resistance poses a formidable global challenge to public health and development. The dire consequences are starkly evident, with an estimated 5 million global deaths directly attributed to bacterial antimicrobial resistance in 2019 alone. This alarming trend threatens the efficacy of commonly used antibiotics against widespread bacterial infections, presenting a critical need for new antibiotic treatments to address the escalating threat of antibiotic resistance.

Furthermore, WHO's collaboration with the global antimicrobial-resistant R&D Hub underscores concerted efforts to address this pressing issue. A joint report for G7 Finance and Health Ministers details progress in incentivizing the development of new antimicrobial treatments, following commitments made in 2021 and 2022. These commitments aim to expedite the implementation of existing antimicrobial resistance strategies, address antibiotic market failures, and foster economic conditions conducive to preserving the effectiveness of essential antibiotics, and bolster antimicrobial resistance research and development. Additionally, the focus is on facilitating the introduction of novel antibacterial medicines that cater to public health needs.

The increasing proactive initiatives by governments and regulatory bodies reflect a growing recognition of the urgency to tackle antimicrobial resistance comprehensively. By fostering collaborative efforts and strategic interventions, these initiatives not only mitigate the immediate risks posed by antimicrobial resistance but also pave the way for sustainable solutions to safeguard public health. Consequently, such concerted actions are poised to play a pivotal role in driving the growth and advancement of the global market for antibiotics resistance.

However, the stringent regulatory requirements and limited novel antibiotic development are some of the key constraints that may limit the growth of the antibiotic resistance market.

Antibiotic Resistance Market Segment Analysis:

Antibiotic resistance market by Disease (Urinary Tract Infections, Bloodstream Infection, Hospital Acquired Pneumonia, and Others), Therapeutic Class (Tetracyclines, Floroquinolones, Amphenicols, Oxazolidinones, and Others), Distribution (Hospital Pharmacies, Retail Pharmacies, And Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the disease segment of the antibiotic resistance market, the urinary tract infection category is estimated to amass the highest revenue share in the antibiotic resistance market in 2023. This can be attributed to the increasing incidence of urinary tract infections. So, the high incidence of urinary tract infections leads to extensive use of antibiotics for treatment, contributing to the development of antibiotic resistance. On the other hand, the growing prevalence of underlying medical conditions such as diabetes and kidney disease are more likely to develop urinary tract infections. Patients with these conditions often have compromised immune systems or other physiological factors that make them more susceptible to infections.

Moreover, treating UTIs in these patients may require the use of antibiotics with broader spectrum coverage to target a wider range of potential pathogens, including drug resistance strains. As a result, the escalating obstacle of treating UTIs efficiently because of antibiotic resistance highlights the immediate necessity for novel therapeutic methodologies, thereby propelling the growth of the antibiotic resistance market.

According to a publication from BioMed Central Ltd published in October 2023, Urinary Tract Infection emerge as a significant public health concern, impacting over 150 million people globally and resulting in an annual economic burden of approximately USD 6 billion. Urinary Tract Infection presents a significant problem for the people, as one of the most widespread infectious diseases, ranking second only to upper respiratory tract infections. According to the same source mentioned above, globally more than 50% of all women and at least 12% of men experience UTIs during their lifetimes. So, the growing prevalence of urinary tract infection creates an opportunity for the antibiotic resistance market.

North America Is Expected To Dominate The Overall Antibiotic Resistance Market:

North America is expected to account for the highest proportion of the antibiotic resistance market in 2023, out of all regions. This is due to the significant rates of antibiotic resistance infections owing to factors such as overuse and misuse of antibiotics. So, this high prevalence of antibiotic resistance necessitates the development and adoption of new antibiotics that will driving the market growth. Additionally, the growing investment and a focus on advancing research and development, and availability of robust healthcare infrastructure are some of the other key factors driving the growth of the Antibiotic Resistance market in North America.

According to The Institute for Health Metrics and Evaluation, in an article released in August 2023, bacterial antimicrobial resistance resulted in 569,000 deaths across all 35 countries within the WHO Region of the Americas.

On the other hand, according to the Pew Charitable Trusts article published in July 2023, antibiotic-resistant bacteria represent a rising danger to public health. Annually, more than 2.8 million infections in the U.S. are resistant to antibiotics, leading to over 35,000 deaths. Moreover, the increasing need for new antibiotic therapies and rising public health concerns and awareness are expected to drive market growth in the forecast period.

Furthermore, the region's governmental initiatives and compulsory insurance policies are expected to drive growth in the upcoming years. In the United States, approximately 85.0% of antibiotics used for treating infections are covered by insurance plans. So, these are some of the major factors that are expected to drive up the growth of the market in the North America Region.

Antibiotic Resistance Market Key Players:

Some of the key market players operating in the Antibiotic Resistance market include Melinta Therapeutics LLC, Basilea Pharmaceutical Ltd, Theravance Biopharma, WOCKHARDT, Paratek Pharmaceuticals, Inc., Seres Therapeutics, AbbVie Inc., Merck & Co., Inc., Pfizer Inc., Johnson & Johnson Services, Inc., Novartis AG, GSK plc., Cipla, F. Hoffmann-La Roche Ltd, Sanofi, Lilly, Bayer AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Viatris Inc., and others.

Recent Developmental Activities In The Antibiotic Resistance Market:

In May 2023, Paratek Pharmaceuticals, Inc. partnered with Zai Lab (Shanghai) Co., Ltd. and collaboratively developed and commercialized omadacycline, an innovative therapy based on tetracycline chemistry, specifically for patients in China.

In May 2023, Melinta Therapeutics, LLC, and Xediton Pharmaceuticals Inc entered into private agreement for the commercialization and licensing of anti-infective products in Canada, including BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products. Under the terms of the agreement, Xediton is responsible for the registration and commercialization of these products in Canada.

Key Takeaways From The Antibiotic Resistance Market Report Study

Market size analysis for current Antibiotic Resistance Market size (2023), and market forecast for 6 years (2024-2030)

Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years

Key companies dominating the global Antibiotic Resistance market.

Various opportunities are available for the other competitors in the Antibiotic Resistance Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Antibiotic Resistance market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Antibiotic Resistance market growth in the coming future?

Target Audience Who Can Benefit From This Antibiotic Resistance Market Report Study

Antibiotic Resistance product providers

Research organizations and consulting companies

Antibiotic resistance-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Antibiotic Resistance Market

Various end-users who want to know more about the Antibiotic Resistance Market and the latest developments in the Antibiotic Resistance Market.

Frequently Asked Questions For The Antibiotic Resistance Market:

1. What is Antibiotic Resistance?

Antibiotic resistance occurs when bacteria develop the ability to survive exposure to antibiotics that were previously effective in killing or inhibiting their growth. This resistance can arise through various mechanisms, such as genetic mutations or the acquisition of resistance genes from other bacteria through horizontal gene transfer.

2. What is the market for antibiotic resistance?

The global antibiotic resistance market is estimated to grow at a CAGR of 5.65% during the forecast period from 2024 to 2030.

3. What are the drivers for the global antibiotic resistance market?

The Antibiotic Resistance Market is slated to witness prosperity owing to factors such as the growing prevalence of antibiotic-resistant infection globally and the growing overuse and misuse of antibiotics during the forecast period (2024-2030).

4. Who are the key players operating in the global antibiotic resistance market?

Some of the key market players operating in antibiotic resistance include Melinta Therapeutics LLC, Basilea Pharmaceutical Ltd, Theravance Biopharma, WOCKHARDT, Paratek Pharmaceuticals, Inc., Seres Therapeutics, AbbVie Inc., Merck & Co., Inc., Pfizer Inc., Johnson & Johnson Services, Inc., Novartis AG, GSK plc., Cipla, F. Hoffmann-La Roche Ltd, Sanofi, Lilly, Bayer AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Viatris Inc., and others.

5. Which region has the highest share in the global antibiotic resistance market?

North America region is expected to dominate the overall antibiotic resistance market during the forecast period from 2024 to 2030. This is due to a growing incidence of antibiotic resistance infections due to overuse and misuse of antibiotics. Additionally, the growing investment and a focus on advancing research and development and the availability of robust healthcare infrastructure in the region are some of the key factors driving the growth of the Antibiotic resistance market in North America.